RDHL

Redhill Biopharma Ltd

Redhill Biopharma Ltd (RDHL) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
D-
Factor Score 0.9 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.3
Rev Growth YoY 58.6%
Gross Margin N/M
Price Return 3M -40.1%
Price Return 12M -50.4%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 13.8
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-04 C+ (2.7) B- (3.1) D- (0.9) C (2.4) C- (1.9) C (2.2)
2026-08-03 C+ (2.7) C+ (2.6) D+ (1.7) C (2.4) C- (2.0) C (2.3)